Infliximab Concentrations in Participants with Moderate to Severe COVID-19

被引：1
|
作者：
Balevic, Stephen J. [1 ,2 ,8 ,9 ]
Dandachi, Dima [3 ]
Dixon, Danielle [4 ]
Hoetelmans, Richard M. W. [5 ]
Bozzette, Sam [6 ]
Mccarthy, Matthew W. [7 ]
机构：
[1] Duke Univ, Sch Med, Dept Med, Durham, NC USA
[2] Duke Univ, Sch Med, Duke Clin Res Inst, Durham, NC USA
[3] Univ Missouri Columbia, Columbia, MO USA
[4] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX USA
[5] Janssen Infect Dis BVBA, Beerse, Belgium
[6] Natl Ctr Advancing Translat Sci, Bethesda, MD USA
[7] Weill Cornell Med, New York, NY USA
[8] Duke Univ, Dept Med, Sch Med, 2301 Erwin Rd,T0909, Durham, NC 27710 USA
[9] Duke Univ, Dept Pediat, Sch Med, 2301 Erwin Rd,T0909, Durham, NC 27710 USA
来源：
JOURNAL OF CLINICAL PHARMACOLOGY | 2024年 / 64卷 / 04期
关键词：
COVID-19; infliximab; pharmacokinetics;
D O I：
10.1002/jcph.2388
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：490 / 491
页数：2
相关论文
共 50 条
  • [1] Adrenomedullin Therapy in Moderate to Severe COVID-19
    Kita, Toshihiro
    Kitamura, Kazuo
    [J]. BIOMEDICINES, 2022, 10 (03)
  • [2] Transfusion Support for Moderate and Severe Cases of COVID-19
    Walker, L.
    Wickenheiser, Z.
    [J]. TRANSFUSION, 2023, 63 : 317A - 318A
  • [3] ABCD Mnemonic in moderate to severe COVID-19 management
    Ahuja, Vanita
    Mahajan, Aastika
    Bevoor, Arun A.
    [J]. JOURNAL OF ANAESTHESIOLOGY CLINICAL PHARMACOLOGY, 2022, 38 : 153 - 154
  • [4] Residual symptoms in moderate to severe COVID-19 patients
    Elfidha, Sabrine
    Louhaichi, Sabrine
    Khalfallah, Ikbel
    Marzouki, Safa
    Kaabi, Line
    Jebeli, Rihab
    Kharrat, Mohamed Ali
    Ammar, Jamel
    Hamdi, Besma
    Hamzaoui, Agnes
    [J]. EUROPEAN RESPIRATORY JOURNAL, 2021, 58
  • [5] The effect of Fingolimod on patients with moderate to severe COVID-19
    Teymouri, Soheil
    Kaleybar, Siamak Pourbayram
    Hejazian, Seyyed Sina
    Hejazian, Seyyedeh Mina
    Ansarin, Khalil
    Ardalan, Mohammadreza
    Vahed, Sepideh Zununi
    [J]. PHARMACOLOGY RESEARCH & PERSPECTIVES, 2023, 11 (01):
  • [6] Remdesivir treatment for patients with moderate to severe COVID-19
    Hasanoglu, Imran
    Guner, Rahmet
    Celik, Ilhami
    Kanat, Fikret
    Batirel, Ayse
    Dizman, Gulcin Telli
    Eren, Esma
    Sevgi, Dilek Yildiz
    Bozkurt, Ilkay
    Yasar, Kadriye Kart
    Senoglu, Sevtap
    Kazak, Esra
    Karaali, Ridvan
    Celikbas, Aysel
    Pullukcu, Husnu
    Cagatay, Arif Atahan
    Unal, Serhat
    Erdinc, Sebnem
    Tabak, Fehmi
    Gul, Ahmet
    Alp, Emine
    [J]. TURKISH JOURNAL OF MEDICAL SCIENCES, 2022, 52 (04) : 880 - 887
  • [7] ABCD Mnemonic in moderate to severe COVID-19 management
    Ahuja, Vanita
    Mahajan, Aastika
    Bevoor, Arun A.
    [J]. JOURNAL OF ANAESTHESIOLOGY CLINICAL PHARMACOLOGY, 2022, 38 (05) : 153 - 154
  • [8] Remdesivir in moderate to severe COVID-19: A matter of time?
    Bonazzetti, Cecilia
    Giacomelli, Andrea
    Pavia, Martina
    Fusetti, Chiara
    Gerbi, Martina
    Petri, Francesco
    Poloni, Andrea
    Oreni, Letizia
    Ridolfo, Anna Lisa
    Antinori, Spinello
    [J]. PHARMACOLOGICAL RESEARCH, 2021, 170
  • [9] Long COVID Among Moderate to Severe COVID-19 Cases in India During Second Wave of COVID-19
    Yadav, Arun Kumar
    Mukherjee, Gautam
    Vasisht, Kundan
    Bobdey, S.
    [J]. ASIA-PACIFIC JOURNAL OF PUBLIC HEALTH, 2022, 34 (08) : 846 - 848
  • [10] Continuous Remote Monitoring in Moderate and Severe COVID-19 Patients
    Rajanna, Avinash H.
    Bellary, Vaibhav S.
    Puranic, Sohani Kashi
    Nayana, C.
    Nagaraj, Jatin Raaghava
    Eshanye, D. A.
    Preethi, K.
    [J]. CUREUS JOURNAL OF MEDICAL SCIENCE, 2023, 15 (09)
12345